Epidermodysplasia verruciformis (EV) is a genodermatosis characterized by widespread and persistent cutaneous lesions caused by β-papillomaviruses. Rare cases of acquired EV-like eruption associated with β-papillomavirus infection have been reported in immunosuppressed patients. We report a case of acquired EV-like eruption in an immunosuppressed patient with adult T-cell leukemia. The cutaneous lesions clinically resembled pityriasis versicolor and exhibited the typical histological features of EV, but in some areas of the same biopsy specimen characteristic homogeneous intracytoplasmic inclusion bodies were observed. Although β-papillomavirus was not detected by highly sensitive polymerase chain reaction, a putative novel type of γ-papillomavirus was identified. This is the first documentation of an association between EV-like eruption and γ-papillomavirus infection.

1.
de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H: Classification of papillomaviruses. Virology 2004;324:17–27.
2.
Orth G: Genetics of epidermodysplasia verruciformis: insights into host defense against papillomaviruses. Semin Immunol 2006;18:362–374.
3.
Ramoz N, Rueda LA, Bouadjar B, Montoya LS, Orth G, Favre M: Mutations in two adjacent novel genes are associated with epidermodysplasia verruciformis. Nat Genet 2002;32:579–581.
4.
Boxman IL, Berkhout RJ, Mulder LH, Wolkers MC, Bouwes Bavinck JN, Vermeer BJ, ter Schegget J: Detection of human papillomavirus DNA in plucked hairs from renal transplant recipients and healthy volunteers. J Invest Dermatol 1997;108:712–715.
5.
Astori G, Lavergne D, Benton C, Hockmayr B, Egawa K, Garbe C, de Villiers EM: Human papillomaviruses are commonly found in normal skin of immunocompetent hosts. J Invest Dermatol 1998;110:752–755.
6.
Boxman IL, Mulder LH, Russell A, Bouwes Bavinck JN, Green A, ter Schegget J: Human papillomavirus type 5 is commonly present in immunosuppressed and immunocompetent individuals. Br J Dermatol 1999;141:246–249.
7.
Forslund O, Antonsson A, Nordin P, Stenquist B, Hansson BG: A broad range of human papillomavirus types detected with a general PCR method suitable for analysis of cutaneous tumours and normal skin. J Gen Virol 1999;80:2437–2443.
8.
Boxman IL, Russell A, Mulder LH, Bavinck JN, ter Schegget J, Green A: Case-control study in a subtropical Australian population to assess the relation between non-melanoma skin cancer and epidermodysplasia verruciformis human papillomavirus DNA in plucked eyebrow hairs. The Nambour Skin Cancer Prevention Study Group. Int J Cancer 2000;86:118–121.
9.
Antonsson A, Forslund O, Ekberg H, Sterner G, Hansson BG: The ubiquity and impressive genomic diversity of human skin papillomaviruses suggest a commensalic nature of these viruses. J Virol 2000;74:11636–11641.
10.
Antonsson A, Erfurt C, Hazard K, Holmgren V, Simon M, Kataoka A, Hossain S, Hakangard C, Hansson BG: Prevalence and type spectrum of human papillomaviruses in healthy skin samples collected in three continents. J Gen Virol 2003;84:1881–1886.
11.
Brink AA, Lloveras B, Nindl I, Heideman DA, Kramer D, Pol R, Fuente MJ, Meijer CJ, Snijders PJ: Development of a general-primer-PCR-reverse-line-blotting system for detection of beta and gamma cutaneous human papillomaviruses. J Clin Microbiol 2005;43:5581–5587.
12.
Harwood CA, Proby CM: Human papillomaviruses and non-melanoma skin cancer. Curr Opin Infect Dis 2002;15:101–114.
13.
Pfister H: Human papillomavirus and skin cancer. J Natl Cancer Inst Monogr 2003;31:52–56.
14.
Sterling JC: Human papillomaviruses and skin cancer. J Clin Virol 2005;32(suppl 1):S67–S71.
15.
Lutzner M, Croissant O, Ducasse MF, Kreis H, Crosnier J, Orth G: A potentially oncogenic human papillomavirus (HPV-5) found in two renal allograft recipients. J Invest Dermatol 1980;75:353–356.
16.
Lutzner MA, Orth G, Dutronquay V, Ducasse MF, Kreis H, Crosnier J: Detection of human papillomavirus type 5 DNA in skin cancers of an immunosuppressed renal allograft recipient. Lancet 1983;2:422–424.
17.
Van der Leest RJ, Zachow KR, Ostrow RS, Bender M, Pass F, Faras AJ: Human papillomavirus heterogeneity in 36 renal transplant recipients. Arch Dermatol 1987;123:354–357.
18.
Rudlinger R, Bunney MH, Smith IW, Hunter JA: Detection of a human papilloma virus type 5 DNA in a renal allograft patient from Scotland. Dermatologica 1988;177:280–286.
19.
Morrison C, Eliezri Y, Magro C, Nuovo GJ: The histologic spectrum of epidermodysplasia verruciformis in transplant and AIDS patients. J Cutan Pathol 2002;29:480–489.
20.
Gross G, Ellinger K, Roussaki A, Fuchs PG, Peter HH, Pfister H: Epidermodysplasia verruciformis in a patient with Hodgkin’s disease: characterization of a new papillomavirus type and interferon treatment. J Invest Dermatol 1988;91:43–48.
21.
Tanigaki T, Kanda R, Sato K: Epidermodysplasia verruciformis (L-L, 1922) in a patient with systemic lupus erythematosus. Arch Dermatol Res 1986;278:247–248.
22.
Holmes C, Chong AH, Tabrizi SN, Downes N, Nindl I: Epidermodysplasia verruciformis-like syndrome in association with systemic lupus erythematosus. Australas J Dermatol 2009;50:44–47.
23.
Prose NS, von Knebel-Doeberitz C, Miller S, Milburn PB, Heilman E: Widespread flat warts associated with human papillomavirus type 5: a cutaneous manifestation of human immunodeficiency virus infection. J Am Acad Dermatol 1990;23:978–981.
24.
Berger TG, Sawchuk WS, Leonardi C, Langenberg A, Tappero J, Leboit PE: Epidermodysplasia verruciformis-associated papillomavirus infection complicating human immunodeficiency virus disease. Br J Dermatol 1991;124:79–83.
25.
Barzegar C, Paul C, Saiag P, Cassenot P, Bachelez H, Autran B, Gorochov G, Petit A, Dubertret L: Epidermodysplasia verruciformis-like eruption complicating human immunodeficiency virus infection. Br J Dermatol 1998;139:122–127.
26.
Haas N, Fuchs PG, Hermes B, Henz BM: Remission of epidermodysplasia verruciformis-like skin eruption after highly active antiretroviral therapy in a human immunodeficiency virus-positive patient. Br J Dermatol 2001;145:669–670.
27.
Trauner MA, Ruben BS, Hatcher SL, Lawry MA: Groin eruption in an HIV-positive man: epidermodysplasia verruciformis (EDV). Arch Dermatol 2002;138:527–532.
28.
Carre D, Dompmartin A, Verdon R, Comoz F, Le Brun E, Freymuth F, Leroy D: Epidermodysplasia verruciformis in a patient with HIV infection: no response to highly active antiretroviral therapy. Int J Dermatol 2003;42:296–300.
29.
Davison SC, Francis N, McLean K, Bunker CB: Epidermodysplasia verruciformis-like eruption associated with HIV infection. Clin Exp Dermatol 2004;29:311–312.
30.
Hu W, Nuovo G, Willen M, Somach S: Epidermodysplasia verruciformis in two half brothers with HIV infection. J Cutan Med Surg 2004;8:357–360.
31.
Kroft EB, Melchers WJ, Blokx WA, de Hoop D, Warris A: A generalized skin eruption in a human immunodeficiency virus-infected boy. J Eur Acad Dermatol Venereol 2008;22:896–897.
32.
Hohenstein E, Rady PL, Hergersberg M, Huber AR, Tyring SK, Bregenzer T, Streit M, Itin P: Epidermodysplasia verruciformis in a HIV-positive patient homozygous for the c917A–>T polymorphism in the TMC8/EVER2 gene. Dermatology 2009;218:114–118.
33.
Rallis E, Paparizos V, Kyriakis K, Katsambas A: Treatment of epidermodysplasia verruciformis in human immunodeficiency virus-positive patients. J Eur Acad Dermatol Venereol 2009;23:195–196.
34.
Rogers HD, Macgregor JL, Nord KM, Tyring S, Rady P, Engler DE, Grossman ME: Acquired epidermodysplasia verruciformis. J Am Acad Dermatol 2009;60:315–320.
35.
Laffort C, Le Deist F, Favre M, Caillat-Zucman S, Radford-Weiss I, Debre M, Fraitag S, Blanche S, Cavazzana-Calvo M, de Saint Basile G, de Villartay JP, Giliani S, Orth G, Casanova JL, Bodemer C, Fischer A: Severe cutaneous papillomavirus disease after haemopoietic stem-cell transplantation in patients with severe combined immune deficiency caused by common gammac cytokine receptor subunit or JAK-3 deficiency. Lancet 2004;363:2051–2054.
36.
Kunishige JH, Hymes SR, Madkan V, Wyatt AJ, Uptmore D, Lazar AJ, Giralt S, Rady P, Tyring S: Epidermodysplasia verruciformis in the setting of graft-versus-host disease. J Am Acad Dermatol 2007;57:S78–S80.
37.
Tsukasaki K, Hermine O, Bazarbachi A, Ratner L, Ramos JC, Harrington W Jr, O’Mahony D, Janik JE, Bittencourt AL, Taylor GP, Yamaguchi K, Utsunomiya A, Tobinai K, Watanabe T: Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting. J Clin Oncol 2009;27:453–459.
38.
Berkhout RJ, Tieben LM, Smits HL, Bavinck JN, Vermeer BJ, ter Schegget J: Nested PCR approach for detection and typing of epidermodysplasia verruciformis-associated human papillomavirus types in cutaneous cancers from renal transplant recipients. J Clin Microbiol 1995;33:690–695.
39.
Egawa K, Delius H, Matsukura T, Kawashima M, de Villiers EM: Two novel types of human papillomavirus, HPV 63 and HPV 65: comparisons of their clinical and histological features and DNA sequences to other HPV types. Virology 1993;194:789–799.
40.
Egawa K: New types of human papillomaviruses and intracytoplasmic inclusion bodies: a classification of inclusion warts according to clinical features, histology and associated HPV types. Br J Dermatol 1994;130:158–166.
41.
Egawa K, Honda Y, Inaba Y, Ono T: Pigmented viral warts: a clinical and histopathological study including human papillomavirus typing. Br J Dermatol 1998;138:381–389.
42.
Spencer ES, Andersen HK: Clinically evident, non-terminal infections with herpesviruses and the wart virus in immunosuppressed renal allograft recipients. Br Med J 1970;3:251–254.
43.
Morison WL: Viral warts, herpes simplex and herpes zoster in patients with secondary immune deficiencies and neoplasms. Br J Dermatol 1975;92:625–630.
44.
Johansson E, Pyrhonen S, Rostila T: Warts and wart virus antibodies in patients with systemic lupus erythematosus. Br Med J 1977;1:74–76.
45.
Ingelfinger JR, Grupe WE, Topor M, Levey RH: Warts in a pediatric renal transplant population. Dermatologica 1977;155:7–12.
46.
Rudlinger R, Smith IW, Bunney MH, Hunter JA: Human papillomavirus infections in a group of renal transplant recipients. Br J Dermatol 1986;115:681–692.
47.
Leigh IM, Glover MT: Skin cancer and warts in immunosuppressed renal transplant recipients. Recent Results Cancer Res 1995;139:69–86.
48.
Gassenmaier A, Fuchs P, Schell H, Pfister H: Papillomavirus DNA in warts of immunosuppressed renal allograft recipients. Arch Dermatol Res 1986;278:219–223.
49.
Jacyk WK, Lechner W: Epidermodysplasia verruciformis in lepromatous leprosy: report of 2 cases. Dermatologica 1984;168:202–205.
50.
Hultgren TL, Srinivasan SK, DiMaio DJ: Epidermodysplasia verruciformis occurring in a patient with human immunodeficiency virus: a case report. Cutis 2007;79:307–311.
51.
Bonamigo R, Maldonado G, Londero RM, Cartell A: Epidermodysplasia verruciformis-like disorder in a teenager with HIV and HCV infections. Pediatr Dermatol 2007;24:456–457.
52.
Antoniou C, Kosmadaki MG, Stratigos AJ, Katsambas AD: Genital HPV lesions and molluscum contagiosum occurring in patients receiving anti-TNF-alpha therapy. Dermatology 2008;216:364–365.
53.
Ohshima K, Jaffe ES, Kikuchi M: Adult T-cell leukaemia/lymphoma; in Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (eds): WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, IARC, 2008, pp 281–284.
54.
Johno M, Ohishi M, Kojo Y, Yamamoto S, Ono T: Cutaneous manifestations of adult T-cell leukemia/lymphoma; in Takatsuki K, Hinuma Y, Yoshida M (eds): Advances in Adult T-Cell Leukemia and HTLV-I Research. Gann Monograph on Cancer Research 39. Tokyo, Japan Scientific Societies Press, 1992, pp 33–42.
55.
Gross G, Pfister H, Hagedorn M, Gissmann L: Correlation between human papillomavirus (HPV) type and histology of warts. J Invest Dermatol 1982;78:160–164.
56.
Croissant O, Breitburd F, Orth G: Specificity of cytopathic effect of cutaneous human papillomaviruses. Clin Dermatol 1985;3:43–55.
57.
Jablonska S, Orth G, Obalek S, Croissant O: Cutaneous warts: clinical, histologic, and virologic correlations. Clin Dermatol 1985;3:71–82.
58.
Kawase M, Honda M, Niimura M: Detection of human papillomavirus type 60 in plantar cysts and verruca plantaris by the in situ hybridization method using digoxigenin labeled probes. J Dermatol 1994;21:709–715.
59.
Egawa K, Kasai S, Hattori N, Saeki Y, Matsuda M, Hino H: A case of a human-papillomavirus-60-induced wart with clinical appearance of both pigmented and ridged warts. Dermatology 1998;197:268–270.
60.
Matsukura T, Iwasaki T, Kawashima M: Molecular cloning of a novel human papillomavirus (type 60) from a plantar cyst with characteristic pathological changes. Virology 1992;190:561–564.
61.
Kashima M, Adachi M, Honda M, Niimura M, Nakabayashi Y: A case of peculiar plantar warts: human papillomavirus type 60 infection. Arch Dermatol 1994;130:1418–1420.
62.
Egawa K, Inaba Y, Ono T, Arao T: ‘Cystic papilloma’ in humans? Demonstration of human papillomavirus in plantar epidermoid cysts. Arch Dermatol 1990;126:1599–1603.
63.
Egawa K, Honda Y, Inaba Y, Ono T, De Villiers EM: Detection of human papillomaviruses and eccrine ducts in palmoplantar epidermoid cysts. Br J Dermatol 1995;132:533–542.
64.
Egawa K, Honda Y, Inaba Y, Kojo Y, Ono T, de Villiers EM: Multiple plantar epidermoid cysts harboring carcinoembryonic antigen and human papillomavirus DNA sequences. J Am Acad Dermatol 1994;30:494–496.
65.
Honda A, Iwasaki T, Sata T, Kawashima M, Morishima T, Matsukura T: Human papillomavirus type 60-associated plantar wart: ridged wart. Arch Dermatol 1994;130:1413–1417.
66.
Tamura K, Dudley J, Nei M, Kumar S: MEGA4: molecular evolutionary genetics analysis (MEGA) software version 4.0. Mol Biol Evol 2007;24:1596–1599.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.